Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Personalised Education Versus Usual Physiotherapy for Acute Rotator Cuff-Related Shoulder Pain

NCT07859891 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-10-17
Last updated
2026-10-06

Condition(s) studied

Rotator Cuff-related Shoulder PainShoulder PainShoulder Disability

Investigational drug(s) / intervention(s)

Personalised, Multimodal Educational InterventionUsual Physiotherapy Care

Personalised, Multimodal Educational Intervention: Participants receive a personalised, multimodal educational intervention over a maximum of 12 weeks. Delivery may combine a written educational guide, a study website hosting video resources, and up to eight individual educational consultations of approximately 30 minutes. The content and the combination of components are agreed between participant and physiotherapist through shared decision making. No structured therapeutic exercise programme is prescribed, and participants in this group do not receive usual physiotherapy care in addition. The intervention aims to improve understanding of shoulder pain, self-management skills, confidence in movement and return to normal activities.

Usual Physiotherapy Care: Participants receive usual physiotherapy care over a maximum of 12 weeks, comprising up to eight supervised consultations of approximately 30 minutes delivered according to current clinical practice. Treatment may combine therapeutic exercise, verbal education, manual therapy and other adjunctive treatments in routine use, at the discretion of the treating physiotherapist.

Study summary

Rotator cuff-related shoulder pain (RCRSP) is one of the most common musculoskeletal disorders presenting in primary care. It is frequently associated with persistent pain, disability, healthcare utilisation and work absenteeism. Exercise-based physiotherapy is recommended as first-line management in clinical practice guidelines, yet its average effects on pain and disability are modest and a substantial proportion of people remain symptomatic several months after onset. Patient education is also recommended, and trials conducted in people with persistent symptoms suggest that education-based care may produce improvements comparable to those obtained with progressive exercise. However, the effectiveness of a structured educational intervention as a first-line management strategy during the acute phase of RCRSP remains unclear.

SHOULD Education lead Rehabilitation? (SHOULD-ER) is a multicentre, pragmatic, parallel-group, non-inferiority randomised controlled trial comparing a personalised, multimodal educational intervention with usual physiotherapy care in adults presenting with acute non-traumatic RCRSP of less than six weeks duration. Participants will be randomly assigned to one of the trial arms for a 12-week treatment period, with follow-up to 24 weeks.

The primary objective is to determine whether the educational intervention is non-inferior to usual physiotherapy care regarding improvement in shoulder pain and disability at 12 weeks, measured by the Shoulder Pain and Disability Index (SPADI). Secondary outcomes include pain-related function, self-efficacy, fear-avoidance beliefs, quality of life, sleep quality, patient satisfaction and healthcare costs.

A nested qualitative study and a within-trial economic evaluation are embedded in the trial. An exploratory analysis of prognostic factors will also be conducted with a secondary analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Able to speak and understand French * Affiliated with a French health insurance system * Available for study follow-up * Clinical diagnosis of acute non-traumatic rotator cuff-related shoulder pain of less than 6 weeks' duration: deltoid-region and/or upper arm pain; pain associated with arm movement; familiar pain reproduced during resisted external rotation testing * Written informed consent obtained Exclusion Criteria: * Previous traumatic shoulder injury potentially causing rotator cuff tear, capsuloligamentous or labral injury, fracture, or dislocation involving the shoulder complex * Clinical signs of massive rotator cuff tear * Referred or cervical radicular pain * Cervical radiculopathy, neuropathic pain or upper-limb neuropathy * Frozen shoulder * Glenohumeral instability * Glenohumeral, acromioclavicular, or sternoclavicular arthropathy * Vascular disorders affecting the upper limb * Inflammatory rheumatic disease affecting the upper limb * Central neurological disease or cancer affecting the shoulder * Previous surgery on the painful shoulder * Current rehabilitation for the present shoulder episode * Opioid use or corticosteroid injection within 3 months or planned at the enrolment * Unable to complete questionnaires * Participation in another clinical trial * Persons under legal protection * Administrative or judicial supervision

Primary outcome measure(s)

  • Change in Shoulder Pain and Disability Index (SPADI) total Score — Baseline to Week 12
    The Shoulder Pain and Disability Index (SPADI) is a 13-item participant-reported questionnaire comprising a five-item pain subscale and an eight-item disability subscale. Items are combined and transformed into a total score ranging from 0 to 100, with higher scores indicating greater shoulder pain and disability. The primary endpoint is the between-group difference in SPADI score change from baseline to Week 12.

Trial sites (1)

FacilityCityRegionStatus
Laboratoire Sport Activité Physique Rééducation et Motricité pour la performance et la santé (SAPRéM) Orléans Loiret

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07859891 on ClinicalTrials.gov ↗ ← All trials in France